annual cash & cash equivalents:
$1.93B-$980.00M(-33.71%)Summary
- As of today (May 20, 2025), MRNA annual cash & cash equivalents is $1.93 billion, with the most recent change of -$980.00 million (-33.71%) on December 31, 2024.
- During the last 3 years, MRNA annual cash & cash equivalents has fallen by -$4.92 billion (-71.86%).
- MRNA annual cash & cash equivalents is now -71.86% below its all-time high of $6.85 billion, reached on December 31, 2021.
Performance
MRNA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.62B-$304.00M(-15.78%)Summary
- As of today (May 20, 2025), MRNA quarterly cash & cash equivalents is $1.62 billion, with the most recent change of -$304.00 million (-15.78%) on March 31, 2025.
- Over the past year, MRNA quarterly cash & cash equivalents has dropped by -$428.00 million (-20.87%).
- MRNA quarterly cash & cash equivalents is now -76.30% below its all-time high of $6.85 billion, reached on December 31, 2021.
Performance
MRNA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
MRNA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.7% | -20.9% |
| 3 y3 years | -71.9% | -67.8% |
| 5 y5 years | +717.0% | +314.3% |
MRNA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -71.9% | at low | -67.8% | at low |
| 5 y | 5-year | -71.9% | +717.0% | -76.3% | +314.3% |
| alltime | all time | -71.9% | >+9999.0% | -76.3% | >+9999.0% |
MRNA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.62B(-15.8%) |
| Dec 2024 | $1.93B(-33.7%) | $1.93B(+17.2%) |
| Sep 2024 | - | $1.64B(-33.7%) |
| Jun 2024 | - | $2.48B(+20.8%) |
| Mar 2024 | - | $2.05B(-29.4%) |
| Dec 2023 | $2.91B(-9.3%) | $2.91B(-0.9%) |
| Sep 2023 | - | $2.93B(-22.9%) |
| Jun 2023 | - | $3.80B(+10.5%) |
| Mar 2023 | - | $3.44B(+7.4%) |
| Dec 2022 | $3.21B(-53.2%) | $3.21B(+5.9%) |
| Sep 2022 | - | $3.03B(+5.4%) |
| Jun 2022 | - | $2.87B(-43.1%) |
| Mar 2022 | - | $5.05B(-26.3%) |
| Dec 2021 | $6.85B(+161.0%) | $6.85B(+23.4%) |
| Sep 2021 | - | $5.55B(-0.9%) |
| Jun 2021 | - | $5.60B(+3.0%) |
| Mar 2021 | - | $5.44B(+107.4%) |
| Dec 2020 | $2.62B(+1012.4%) | $2.62B(+74.3%) |
| Sep 2020 | - | $1.51B(-14.5%) |
| Jun 2020 | - | $1.76B(+349.7%) |
| Mar 2020 | - | $391.72M(+66.1%) |
| Dec 2019 | $235.88M(-64.2%) | $235.88M(+35.8%) |
| Sep 2019 | - | $173.71M(+14.6%) |
| Jun 2019 | - | $151.62M(-69.9%) |
| Mar 2019 | - | $502.93M(-23.6%) |
| Dec 2018 | $658.36M(+388.2%) | $658.36M(+294.1%) |
| Sep 2018 | - | $167.06M(+23.9%) |
| Dec 2017 | $134.86M(+169.3%) | $134.86M(>+9900.0%) |
| Sep 2017 | - | $8700.00(-96.7%) |
| Jun 2017 | - | $263.90K(+22.0%) |
| Mar 2017 | - | $216.40K(+105.5%) |
| Dec 2016 | $50.08M(+6953.5%) | - |
| Dec 2016 | - | $105.30K(+31.6%) |
| Sep 2016 | - | $80.00K(-75.1%) |
| Jun 2016 | - | $321.00K(+4.6%) |
| Mar 2016 | - | $307.00K(-56.8%) |
| Dec 2015 | $710.00K(-61.1%) | $710.00K(-45.9%) |
| Sep 2015 | - | $1.31M(+80.9%) |
| Jun 2015 | - | $726.00K(-37.6%) |
| Mar 2015 | - | $1.16M(-36.2%) |
| Dec 2014 | $1.82M(+100.7%) | $1.82M(-43.1%) |
| Sep 2014 | - | $3.20M(-25.8%) |
| Jun 2014 | - | $4.32M(-21.8%) |
| Mar 2014 | - | $5.52M(+507.3%) |
| Dec 2013 | $909.00K(+320.8%) | $909.00K(+106.1%) |
| Sep 2013 | - | $441.00K(+354.6%) |
| Jun 2013 | - | $97.00K(-2.0%) |
| Mar 2013 | - | $99.00K(-54.2%) |
| Dec 2012 | $216.00K(-77.9%) | $216.00K(-47.7%) |
| Sep 2012 | - | $413.00K(+330.2%) |
| Jun 2012 | - | $96.00K(-78.0%) |
| Mar 2012 | - | $437.00K(-55.2%) |
| Dec 2011 | $976.00K(-8.4%) | $976.00K(-6.5%) |
| Sep 2011 | - | $1.04M(-77.8%) |
| Jun 2011 | - | $4.71M(+318.6%) |
| Mar 2011 | - | $1.12M(+5.4%) |
| Dec 2010 | $1.07M(+42.5%) | $1.07M(+42.5%) |
| Sep 2010 | - | $748.00K(-30.4%) |
| Jun 2010 | - | $1.07M(-59.2%) |
| Mar 2010 | - | $2.63M(+251.6%) |
| Dec 2009 | $748.00K | $748.00K(-78.2%) |
| Sep 2009 | - | $3.43M(-56.7%) |
| Jun 2009 | - | $7.93M(+43.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2009 | - | $5.53M(+410.3%) |
| Dec 2008 | $1.08M(-96.1%) | $1.08M(-87.6%) |
| Sep 2008 | - | $8.72M(-47.5%) |
| Jun 2008 | - | $16.61M(+5.6%) |
| Mar 2008 | - | $15.73M(-43.2%) |
| Dec 2007 | $27.70M(-2.7%) | $27.70M(-32.9%) |
| Sep 2007 | - | $41.30M(-22.1%) |
| Jun 2007 | - | $53.04M(+6.0%) |
| Mar 2007 | - | $50.05M(+75.7%) |
| Dec 2006 | $28.48M(+6.4%) | $28.48M(+35.1%) |
| Sep 2006 | - | $21.08M(-21.6%) |
| Jun 2006 | - | $26.87M(+26.4%) |
| Mar 2006 | - | $21.25M(-20.6%) |
| Dec 2005 | $26.77M(+3.8%) | $26.77M(+68.2%) |
| Sep 2005 | - | $15.91M(+43.6%) |
| Jun 2005 | - | $11.08M(-40.2%) |
| Mar 2005 | - | $18.52M(-28.2%) |
| Dec 2004 | $25.80M(+53.6%) | $25.80M(+90.5%) |
| Sep 2004 | - | $13.54M(-16.8%) |
| Jun 2004 | - | $16.28M(+45.5%) |
| Mar 2004 | - | $11.19M(-33.4%) |
| Dec 2003 | $16.79M(+86.1%) | $16.79M(-27.4%) |
| Sep 2003 | - | $23.13M(+39.5%) |
| Jun 2003 | - | $16.58M(-1.8%) |
| Mar 2003 | - | $16.88M(+87.1%) |
| Dec 2002 | $9.02M(-23.3%) | $9.02M(-36.1%) |
| Sep 2002 | - | $14.11M(-24.5%) |
| Jun 2002 | - | $18.69M(+5.9%) |
| Mar 2002 | - | $17.65M(+50.1%) |
| Dec 2001 | $11.76M(+88.0%) | $11.76M(+64.5%) |
| Sep 2001 | - | $7.15M(-5.9%) |
| Jun 2001 | - | $7.60M(-12.9%) |
| Mar 2001 | - | $8.73M(+39.5%) |
| Dec 2000 | $6.26M(-41.5%) | $6.26M(-20.8%) |
| Sep 2000 | - | $7.90M(-18.2%) |
| Jun 2000 | - | $9.65M(-9.9%) |
| Mar 2000 | - | $10.72M(+0.2%) |
| Dec 1999 | $10.70M(-54.5%) | $10.70M(-40.6%) |
| Sep 1999 | - | $18.00M(-11.8%) |
| Jun 1999 | - | $20.40M(-8.5%) |
| Mar 1999 | - | $22.30M(-5.1%) |
| Dec 1998 | $23.50M(-7.1%) | $23.50M(-3.3%) |
| Sep 1998 | - | $24.30M(-0.8%) |
| Jun 1998 | - | $24.50M(+18.4%) |
| Mar 1998 | - | $20.70M(-18.2%) |
| Dec 1997 | $25.30M(+462.2%) | $25.30M(-3.4%) |
| Sep 1997 | - | $26.20M(+3.6%) |
| Jun 1997 | - | $25.30M(+8.6%) |
| Mar 1997 | - | $23.30M(+1692.3%) |
| Dec 1996 | $4.50M(+12.5%) | - |
| Sep 1996 | - | $1.30M(-67.5%) |
| Jun 1996 | $4.00M(0.0%) | $4.00M(+1233.3%) |
| Mar 1996 | - | $300.00K(-25.0%) |
| Dec 1995 | - | $400.00K(-42.9%) |
| Sep 1995 | - | $700.00K(-82.5%) |
| Jun 1995 | $4.00M(+25.0%) | $4.00M(+110.5%) |
| Mar 1995 | - | $1.90M(-5.0%) |
| Dec 1994 | - | $2.00M(-48.7%) |
| Sep 1994 | - | $3.90M(+21.9%) |
| Jun 1994 | $3.20M | $3.20M(0.0%) |
| Mar 1994 | - | $3.20M(-5.9%) |
| Dec 1993 | - | $3.40M(+580.0%) |
| Sep 1993 | - | $500.00K |
FAQ
- What is Moderna annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Moderna?
- What is Moderna annual cash & cash equivalents year-on-year change?
- What is Moderna quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Moderna?
- What is Moderna quarterly cash & cash equivalents year-on-year change?
What is Moderna annual cash & cash equivalents?
The current annual cash & cash equivalents of MRNA is $1.93B
What is the all time high annual cash & cash equivalents for Moderna?
Moderna all-time high annual cash & cash equivalents is $6.85B
What is Moderna annual cash & cash equivalents year-on-year change?
Over the past year, MRNA annual cash & cash equivalents has changed by -$980.00M (-33.71%)
What is Moderna quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of MRNA is $1.62B
What is the all time high quarterly cash & cash equivalents for Moderna?
Moderna all-time high quarterly cash & cash equivalents is $6.85B
What is Moderna quarterly cash & cash equivalents year-on-year change?
Over the past year, MRNA quarterly cash & cash equivalents has changed by -$428.00M (-20.87%)